shadow shadow shadow shadow shadow
    Country
    Opportunity Status
    Funding Instrument Type
    Category
    Clear

    Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)

    PAR-24-064

    National Institutes of Health

    Opening date 27 Feb 2024, 12:00AM

    Closing date 19 Nov 2026, 12:00AM

    Funding Opportunity Number: PAR-24-064

    Opportunity Category: Discretionary

    CFDA Number(s): 93.279 -- Drug Abuse and Addiction Research Programs

    Cost Sharing or Matching Requirement: No

    Posted Date: Feb 27, 2024 12:00:00 AM EST

    Closing Date: Nov 19, 2026 12:00:00 AM EST

    Award Ceiling: none

    Award Floor: none

    Eligible Applicants: Independent school districts,Others (see text field entitled "Additional Information on Eligibility" for clarification),Special district governments,For profit organizations other than small businesses,Public and State controlled institutions of higher education,State governments,City or township governments,Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education,Small businesses,Native American tribal governments (Federally recognized),Private institutions of higher education,County governments,Public housing authorities/Indian housing authorities,Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education,Native American tribal organizations (other than Federally recognized tribal governments)

    Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

    Agency Name: National Institutes of Health

    Description: The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of Digital Therapeutics (DTx) to treat Substance Use Disorders (SUDs). Advances in technology offer unprecedented opportunities to develop clinical-grade mobile, web, or other software-based platforms designed to deliver treatments that are safe and effective for SUD. FDA authorization of DTx can play an important role in increasing the availability of treatments to patients with SUD, although there are other pathways for dissemination of this class of intervention. The primary objective of this FOA is to move DTx to their next step in the development process, with the ultimate goal of generating new, FDA authorized, disseminated treatments for SUDs. Applications may focus on the pre-clinical and/or clinical development and testing of new DTx or existing DTx developed for other indications.

    Grantor Contact Information: NIH Grants Information grantsinfo@nih.gov

    We use cookies and similar technologies that are necessary to operate the website.Please read our cookie policy.

    We use cookies and similar technologies that are necessary to operate the website. Additional cookies are only used with your consent. We use the additional cookies to perform analyses of website usage and to check marketing measures for their efficiency. These analyses are carried out to provide you with a better user experience on the website. You are free to give, deny, or withdraw your consent at any time by using the "cookie settings" link at the bottom of each page. You can consent to our use of cookies by clicking "Agree". For more information about what information is collected and how it is shared with our partners, please read our cookie policy.

    • Required to run the website
    • Monitoring website usage and optimizing the user experience
    • Evaluation of marketing actions
    • Storage of your preferences from previous visits
    • Collecting user feedback to improve our website
    • Recording of your interests in order to provide customised content and offers
    Cookie Settings Accept